| New aspects of natural-killer-cell surveillance and therapy of cancer MJ Smyth, Y Hayakawa, K Takeda, H Yagita Nature Reviews Cancer 2 (11), 850-861, 2002 | 1010 | 2002 |
| Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells K Takeda, Y Hayakawa, MJ Smyth, N Kayagaki, N Yamaguchi, S Kakuta, ... Nature medicine 7 (1), 94-100, 2001 | 965 | 2001 |
| Activation of NK cell cytotoxicity MJ Smyth, E Cretney, JM Kelly, JA Westwood, SEA Street, H Yagita, ... Molecular immunology 42 (4), 501-510, 2005 | 956 | 2005 |
| CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity Y Hayakawa, MJ Smyth The Journal of Immunology 176 (3), 1517-1524, 2006 | 871 | 2006 |
| Critical contribution of liver natural killer T cells to a murine model of hepatitis K Takeda, Y Hayakawa, L Van Kaer, H Matsuda, H Yagita, K Okumura Proceedings of the National Academy of Sciences 97 (10), 5498-5503, 2000 | 637 | 2000 |
| Critical role for tumor necrosis factor–related apoptosis-inducing ligand in immune surveillance against tumor development K Takeda, MJ Smyth, E Cretney, Y Hayakawa, N Kayagaki, H Yagita, ... The Journal of experimental medicine 195 (2), 161-169, 2002 | 621 | 2002 |
| CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer MJ Smyth, MWL Teng, J Swann, K Kyparissoudis, DI Godfrey, ... The Journal of Immunology 176 (3), 1582-1587, 2006 | 584 | 2006 |
| Cytokines in cancer immunity and immunotherapy MJ Smyth, E Cretney, MH Kershaw, Y Hayakawa Immunological reviews 202 (1), 275-293, 2004 | 510 | 2004 |
| Nature's TRAIL—on a path to cancer immunotherapy MJ Smyth, K Takeda, Y Hayakawa, JJ Peschon, MRM Van Den Brink, ... Immunity 18 (1), 1-6, 2003 | 477 | 2003 |
| Differential antitumor immunity mediated by NKT cell subsets in vivo NY Crowe, JM Coquet, SP Berzins, K Kyparissoudis, R Keating, ... The Journal of experimental medicine 202 (9), 1279-1288, 2005 | 453 | 2005 |
| NKG2D function protects the host from tumor initiation MJ Smyth, J Swann, E Cretney, N Zerafa, WM Yokoyama, Y Hayakawa The Journal of experimental medicine 202 (5), 583-588, 2005 | 431 | 2005 |
| IL-21 induces the functional maturation of murine NK cells J Brady, Y Hayakawa, MJ Smyth, SL Nutt The Journal of Immunology 172 (4), 2048-2058, 2004 | 397 | 2004 |
| NKT cells—conductors of tumor immunity? MJ Smyth, NY Crowe, Y Hayakawa, K Takeda, H Yagita, DI Godfrey Current opinion in immunology 14 (2), 165-171, 2002 | 388 | 2002 |
| Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells NY Crowe, AP Uldrich, K Kyparissoudis, KJL Hammond, Y Hayakawa, ... The Journal of Immunology 171 (8), 4020-4027, 2003 | 384 | 2003 |
| Type I IFN contributes to NK cell homeostasis, activation, and antitumor function JB Swann, Y Hayakawa, N Zerafa, KCF Sheehan, B Scott, RD Schreiber, ... The Journal of Immunology 178 (12), 7540-7549, 2007 | 374 | 2007 |
| NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation ND Huntington, H Tabarias, K Fairfax, J Brady, Y Hayakawa, ... the Journal of Immunology 178 (8), 4764-4770, 2007 | 349 | 2007 |
| The dark side of IFN-γ: its role in promoting cancer immunoevasion M Mojic, K Takeda, Y Hayakawa International journal of molecular sciences 19 (1), 89, 2017 | 341 | 2017 |
| TRAIL and its receptors as targets for cancer therapy H Yagita, K Takeda, Y Hayakawa, MJ Smyth, K Okumura Cancer science 95 (10), 777-783, 2004 | 339 | 2004 |
| A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance M Terabe, J Swann, E Ambrosino, P Sinha, S Takaku, Y Hayakawa, ... The Journal of experimental medicine 202 (12), 1627-1633, 2005 | 337 | 2005 |
| TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver K Takeda, E Cretney, Y Hayakawa, T Ota, H Akiba, K Ogasawara, ... Blood 105 (5), 2082-2089, 2005 | 321 | 2005 |
